A win for Apellis, a setback for Astellas

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Lots today from the American Heart Association’s annual meeting, plus former National Cancer Institute chief Ned Sharpless launches a new biotech called Jupiter.

The need-to-know this morning

• The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less frequent injections and include data showing the effect of the drug over two years. The setback is a win for Apellis Pharmaceuticals, which sells a competing eye drug called Syfovre.
• Cytokinetics and Bayer signed a partnership agreement that gives Bayer the right to develop and sell Cytokinetics’ heart drug aficamten in Japan.

Lipoprotein(a) studies make waves at AHA

Two drugs targeting lipoprotein(a) are showing promise in cardiovascular disease, Phase 2 data presented at the American Heart Association show. High levels of lipoprotein(a) indicate a genetic risk factor for cardiovascular disease. This affects 1 out of 5 people worldwide, STAT’s Liz Cooney writes.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In